Ismael Obaidi

Dr. Ismael Obaidi

Trinity College Dublin, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Biotechnology Advances
Verified
Journal Article
Closed access
RORoisin O'Flaherty
Roisin O'Flaherty
ABAdam Bergin
Adam Bergin
EFEvangelia Flampouri
Evangelia Flampouri
LMLetícia Martins Mota
Letícia Martins Mota
IOIsmael Obaidi
Ismael Obaidi
MBMichael Butler
Michael Butler

17 January 2019 in Oncology Letters
Verified
Journal Article
Open access
PDF file
MHMichael Higgins
Michael Higgins
IOIsmael Obaidi
Ismael Obaidi
TMTara Mcmorrow
Tara Mcmorrow
Primary cilia are microtubule‑based organelles that are expressed on almost all mammalian cells. It has become apparent that these structures are important signaling hubs that serve crucial roles in Wnt, hedgehog, extracellular signal‑regulated kinase (ERK)/mitogen‑activated protein kinase (MAPK) and Notch signaling pathways. A number of diseases have been found to involve dysfunctional primary cilia; collectively these diseases are called ciliopathies. In recent years, there has been more focus on the association between primary cilia and cancer, including renal, pancreatic and breast cancer. Numerous studies have demonstrated that various types of cancer cells fail to express cilia. Notably, it has also been indicated that a number of renal carcinogens induce a significant loss of cilia in renal epithelial cells. The present review focuses on the existing literature regarding primary cilia and their involvement with cancer signaling pathways, providing a brief overview of the structural features and functions of primary cilia, then discussing the evidence associating primary cilia with cancer, and presenting the available information on the ERK/MAPK, hedgehog and Wnt signaling pathways, and their involvement in primary cilia in association with cancer.

1 May 2020 in Biology
Verified
Journal Article
Open access
PDF file
IOIsmael Obaidi
Ismael Obaidi
HCHilary Cassidy
Hilary Cassidy
VGVerónica Ibáñez Gaspar
Verónica Ibáñez Gaspar
JMJasmin McCaul
Jasmin McCaul
MHMichael Higgins
Michael Higgins
TMTara Mcmorrow
Tara Mcmorrow
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), is a selective anticancer cytokine capable of exerting a targeted therapy approach. Disappointingly, recent research has highlighted the development of TRAIL resistance in cancer cells, thus minimising its usefulness in clinical settings. However, several recent studies have demonstrated that cancer cells can be sensitised to TRAIL through the employment of a combinatorial approach, utilizing TRAIL in conjunction with other natural or synthetic anticancer agents. In the present study, the chemo-sensitising effect of curcumin on TRAIL-induced apoptosis in renal carcinoma cells (RCC) was investigated. The results indicate that exposure of kidney cancer ACHN cells to curcumin sensitised the cells to TRAIL, with the combination treatment of TRAIL and curcumin synergistically targeting the cancer cells without affecting the normal renal proximal tubular epithelial cells (RPTEC/TERT1) cells. Furthermore, this combination treatment was shown to induce caspase-dependent apoptosis, inhibition of the proteasome, induction of ROS, upregulation of death receptor 4 (DR4), alterations in mitogen-activated protein kinase (MAPK) signalling and induction of endoplasmic reticulum stress. An in vivo zebrafish embryo study demonstrated the effectiveness of the combinatorial regime to inhibit tumour formation without affecting zebrafish embryo viability or development. Overall, the results arising from this study demonstrate that curcumin has the ability to sensitise TRAIL-resistant ACHN cells to TRAIL-induced apoptosis.

2 May 2018 in Current Pharmaceutical Design
Verified
Journal Article
Open access
PDF file
IOIsmael Obaidi
Ismael Obaidi
MHMichael Higgins
Michael Higgins
BBBojlul Bahar
Bojlul Bahar
JDJessica Davis
Jessica Davis
TMTara Mcmorrow
Tara Mcmorrow
Background: Potassium bromate (KBrO3), a food additive, has been used in many bakery products as an oxidizing agent. It has been shown to induce renal cancer in many in-vitro and in-vivo experimental models. Objectives: This study evaluated the carcinogenic potential of potassium bromate (KBrO3) and the chemopreventive mechanisms of the anti-oxidant and anti-inflammatory phytochemical, curcumin against KBrO3-induced carcinogenicity. Method: Lactate dehydrogenase (LDH) cytotoxicity assay and morphological characteristics were used to assess curcumin's cytoprotective potential against KBrO3 toxicity. To assess the chemopreventive potential of curcumin against KBrO3-induced oxidative insult, intracellular H2O2 and the nuclear concentration of the DNA adduct 8- OHdG were measured. PCR array, qRT-PCR, and western blot analysis were used to identify dysregulated genes by KBrO3 exposure. Furthermore, immunofluorescence was used to evaluate the ciliary loss and the disturbance of cellular tight junction induced by KBrO3. Results: Oxidative stress assays showed that KBrO3 increased the levels of intracellular H2O2 and the DNA adduct 8-OHdG. Combination of curcumin with KBrO3 efficiently reduced the level of H2O2 and 8-OHdG while upregulating the expression of catalase. PCR array, qRT-PCR, and western blot analysis revealed that KBrO3 dysregulated multiple genes involved in inflammation, proliferation, and apoptosis, namely CTGF, IL-1, and TRAF3. Moreover, qRT-PCR and immunofluorescence studies showed that KBrO3 negatively affected the tight junctional protein (ZO-1) and induced a degeneration of primary ciliary proteins. The negative impact of KBrO3 on cilia was markedly repressed by curcumin. Conclusion: Curcumin could potentially be used as a protective agent against carcinogenicity of KBrO3.

5 May 2024 in Review of Clinical Pharmacology and Pharmacokinetics - International Edition
Verified
Journal Article
Closed access
IOIsmael Obaidi
Ismael Obaidi
FAFatimah Adnan Alzubaidi
Fatimah Adnan Alzubaidi
ABAymen A. Bash
Aymen A. Bash
QFQayssar Joudah Fadheel
Qayssar Joudah Fadheel
HAHussam Al-Humadi
Hussam Al-Humadi
JLJunying Liu
Junying Liu
Renal cell carcinoma (RCC) is the most common type of kidney cancer, accounting for 90% of all estimated cases. Advanced RCC often carries poor prognosis due to its high metastases rate, the lack of early-warning signs, as well as its complex clinical manifestations and its resistance to chemotherapy. Ethnopharmacologically, Fructus Rosae laevigata (JinYingZi) has been employed by Chinese medicine to treat various urinary tract and gastrointestinal dis¬orders. This study aimed at performing a series of mechanistic analyses in order to unlock the anticancer potential of JinYingZi-derived bioactive components against RCC. Several network pharmacology tools were employed so as to analyse the drug-disease interactions. Our data revealed that more than 2,214 genes were dysregulated in RCC, whereas the JinYingZi-derived bioactive compounds modulated 347 genes. The intersecting between RCC and the bioactive compounds revealed 132 cross targets. Our results were further validated by conducting molecular docking, which revealed a stable association between oleanolic acid with each of the following targets: androgen receptor (AR), dipeptidyl peptidase (DPP), estradiol (ESR1), nitric oxide synthase 2 (NOS2), and cyclooxygenase-2 (PTGS2). Our approach is being used successfully in order to evaluate a panel of novel medicinal plant-derived bioactive com¬pounds, and may lead to the identification of safe and effective chemical scaffolds that could act as templates for drug discovery or yield potential drug candidates.

16 May 2018
Verified
Book Chapter
Open access
PDF file
MHMichael Higgins
Michael Higgins
IOIsmael Obaidi
Ismael Obaidi
TMTara Mcmorrow
Tara Mcmorrow
This chapter examines a number of different aspects of renal cancer. Firstly, an introduction into the numerous forms of renal cancers is provided, focusing on renal cell carcinomas their causes and the different treatment options currently available. This chapter also takes a look at renal cancer from a toxicological point of view. Due to the crucial role of the kidneys in blood filtration, this allows them to become susceptible to the exposure and accumulation of potentially carcinogenic chemicals. For this reason, renal carcinogens are looked at in detail focusing on the varying mechanisms of genotoxic renal carcinogens such as aristolochic acid and potassium bromate, and their non-genotoxic renal carcinogens counterparts including ochratoxin A and chlorothalonil. This chapter also examines the different methods currently used to detect a compound’s carcinogenic potential, including the in vitro Ames test and animal based carcinogenicity screening methods.